JP2011501656A5 - - Google Patents

Download PDF

Info

Publication number
JP2011501656A5
JP2011501656A5 JP2010527128A JP2010527128A JP2011501656A5 JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5 JP 2010527128 A JP2010527128 A JP 2010527128A JP 2010527128 A JP2010527128 A JP 2010527128A JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
seq
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011501656A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/077622 external-priority patent/WO2009042746A1/en
Publication of JP2011501656A publication Critical patent/JP2011501656A/ja
Publication of JP2011501656A5 publication Critical patent/JP2011501656A5/ja
Pending legal-status Critical Current

Links

JP2010527128A 2007-09-26 2008-09-25 新規抗体 Pending JP2011501656A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97547107P 2007-09-26 2007-09-26
PCT/US2008/077622 WO2009042746A1 (en) 2007-09-26 2008-09-25 Novel antibodies

Publications (2)

Publication Number Publication Date
JP2011501656A JP2011501656A (ja) 2011-01-13
JP2011501656A5 true JP2011501656A5 (enExample) 2011-11-10

Family

ID=40329277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527128A Pending JP2011501656A (ja) 2007-09-26 2008-09-25 新規抗体

Country Status (22)

Country Link
US (3) US7973138B2 (enExample)
EP (1) EP2200700B1 (enExample)
JP (1) JP2011501656A (enExample)
KR (1) KR20100065162A (enExample)
CN (1) CN101888878B (enExample)
AR (1) AR066170A1 (enExample)
AU (1) AU2008304452B2 (enExample)
BR (1) BRPI0816049A2 (enExample)
CA (1) CA2698609A1 (enExample)
CL (1) CL2008002856A1 (enExample)
CO (1) CO6260094A2 (enExample)
DK (1) DK2200700T3 (enExample)
HR (1) HRP20160308T1 (enExample)
HU (1) HUE027911T2 (enExample)
MX (1) MX2010003325A (enExample)
MY (1) MY151191A (enExample)
NZ (1) NZ584838A (enExample)
PE (1) PE20091029A1 (enExample)
RU (1) RU2490277C2 (enExample)
SI (1) SI2200700T1 (enExample)
TW (1) TWI547503B (enExample)
WO (1) WO2009042746A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック, インコーポレイテッド 新規な抗α5β1抗体及びその使用
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
SG175891A1 (en) * 2009-05-08 2011-12-29 Genentech Inc Humanized anti-egfl7 antibodies and methods using same
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
KR102023401B1 (ko) 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
US10023638B2 (en) * 2012-12-26 2018-07-17 Oncosynergy, Inc. Anti-integrin β1 antibody compositions and methods of use thereof
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
US9963513B2 (en) * 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CN108693004B (zh) * 2018-05-24 2020-08-04 中国农业科学院农业质量标准与检测技术研究所 一种检测菜籽粕中是否掺杂抗生素滤渣的方法
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114688461B (zh) * 2020-12-31 2025-02-28 青岛海尔施特劳斯水设备有限公司 一种漏水检测方法及系统
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN114073996B (zh) * 2021-11-24 2023-04-14 中山大学 一种嵌套式微井阵列芯片及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
DE69930723T2 (de) 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DK1075277T4 (da) 1998-05-08 2012-12-17 Univ California Fremgangsmåder til detektion og inhibering af angiogenese
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
MXPA02001439A (es) 1999-08-11 2002-08-30 Eos Biotechnology Inc Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis.
US20020019330A1 (en) 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040009494A1 (en) 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20020015970A1 (en) 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス, インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2002102235A2 (en) 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2003256307A1 (en) 2002-06-25 2004-01-06 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
EP1539247A4 (en) 2002-07-16 2007-08-29 Univ New Jersey Med ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1575516B1 (en) 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
ATE531388T1 (de) * 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
EP1957476A1 (en) 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
EP2091916A2 (en) 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
JP2009526032A (ja) 2006-02-09 2009-07-16 アストラゼネカ アクチボラグ 化合物
CA2646611A1 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
WO2007134876A2 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
AU2009212442C1 (en) 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses

Similar Documents

Publication Publication Date Title
CN112646031B (zh) 抗4-1bb纳米抗体及其用途
US9758586B2 (en) Chimeric rabbit/human ROR1 antibodies
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
DK2493503T3 (en) DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP2009536921A5 (enExample)
JP2012521218A5 (enExample)
JP2017522861A5 (enExample)
EP3008093A1 (en) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
RU2013108054A (ru) Антитела против а2 тенасцина с и способы их применения
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
TWI879889B (zh) 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途
CN111825766B (zh) 抗il-4r单域抗体及其应用
US10519246B2 (en) Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis
WO2021047386A1 (zh) 靶向caix抗原的纳米抗体及其应用
CN109265547A (zh) 一种抗cd47抗体及其应用
JP2024054123A (ja) 癌の治療のための配合剤
CN106164094A (zh) 双特异性抗原结合多肽
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
JP7643752B2 (ja) 抗pd-l1抗体およびその用途
WO2023066389A1 (zh) 靶向pd-1的双特异性抗体、及其制备和应用
EP4435006A1 (en) Bispecific antibody and use thereof
US20250109206A1 (en) Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
RU2761638C1 (ru) Антитела против лиганда программируемой смерти (pd-l1) и их применение
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체